Cav2.1 P Q Type Calcium Channel is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Cav2.1 (CACNA1A) is a voltage-gated calcium channel that mediates P/Q-type calcium currents in neurons. Cav2.1 channels control neurotransmitter release at presynaptic terminals and are essential for synaptic transmission, motor coordination, and cerebellar function. [1]
This protein is involved in: [2]
| Attribute | Value | [3]
|-----------|-------| [4]
| Protein Name | Cav2.1 (P/Q-type) |
| Gene | CACNA1A |
| UniProt ID | O00555 |
| PDB IDs | 6CM4, 7MJ7 |
| Molecular Weight | ~270 kDa |
| Subcellular Localization | Presynaptic terminals, dendritic spines |
| Protein Family | High-voltage activated calcium channel family |
The Cav2.1 channel is a multimeric complex:
Each α1 subunit contains:
| Drug/Agent | Mechanism | Status |
|---|---|---|
| Ziconotide | ω-conotoxin MVIIA block | Approved for pain |
| Flunarizine | Non-selective block | Used for migraine |
| Ethosuximide | T-type specific | Approved for absence seizures |
| Nimodipine | L-type block | Used for migraine prevention |
Cav2.1 (P/Q-type) is the predominant presynaptic calcium channel:
Key characteristics:
Cav2.1 is essential for:
| Disorder | Relationship | Mechanism |
|---|---|---|
| Ataxia | Mutations cause | Channel dysfunction |
| Epilepsy | Risk factor | Altered excitability |
| Migraine | Associated | Cortical spreading depression |
| Alzheimer's | Therapeutic target | Aβ effects on channels |
| Agent | Mechanism | Clinical Status |
|---|---|---|
| Ziconotide | ω-conotoxin MVIIA | FDA approved (pain) |
| Gabapentin | α2δ subunit binding | FDA approved (neuropathic pain) |
| Ethosuximide | T-type (not Cav2.1) | FDA approved (absence seizures) |
The study of Cav2.1 P Q Type Calcium Channel has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.